We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

56 hedge funds and large institutions have $59.3M invested in NeuBase Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

14,400% more call options, than puts

Call options by funds: $145K | Put options by funds: $1K

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

21% more capital invested

Capital invested by funds: $49M → $59.3M (+$10.3M)

6% more funds holding

Funds holding: 53 → 56 (+3)

Holders
56
Holders Change
+3
Holders Change %
+5.66%
% of All Funds
0.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
19
Reduced
15
Closed
8
Calls
$145K
Puts
$1K
Net Calls
+$144K
Net Calls Change
+$127K

Top Buyers

1
PAMP
Polar Asset Management Partners
Ontario, Canada
+$5.75M
2
JAMONY
Jacob Asset Management of New York
California
+$1.2M
3
GCM
Glenview Capital Management
New York
+$906K
4
SCM
Sio Capital Management
New York
+$906K
5
Two Sigma Investments
Two Sigma Investments
New York
+$837K

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$2.05M
2
GCP
GSA Capital Partners
United Kingdom
-$546K
3
Citadel Advisors
Citadel Advisors
Florida
-$255K
4
Wells Fargo
Wells Fargo
California
-$240K
5
N
Nuveen
North Carolina
-$192K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$15M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$7.09M +$308K +1,697 +4%
BlackRock
3
BlackRock
New York
$6.87M +$1.45K +8 +0%
PAMP
4
Polar Asset Management Partners
Ontario, Canada
$4.69M +$5.75M +31,731 New
SCM
5
Sio Capital Management
New York
$2.91M +$906K +5,000 +34%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$2.33M +$558K +3,079 +24%
PCM
7
Prelude Capital Management
New York
$2.3M – – –
State Street
8
State Street
Massachusetts
$1.91M +$24.6K +136 +1%
JAMONY
9
Jacob Asset Management of New York
California
$1.74M +$1.2M +6,600 +128%
Renaissance Technologies
10
Renaissance Technologies
New York
$1.45M -$2.05M -11,325 -54%
Northern Trust
11
Northern Trust
Illinois
$1.35M -$145K -798 -8%
FWM
12
Frontier Wealth Management
Missouri
$1.07M – – –
Bank of New York Mellon
13
Bank of New York Mellon
New York
$909K -$14K -77 -1%
Goldman Sachs
14
Goldman Sachs
New York
$770K +$135K +743 +17%
GCM
15
Glenview Capital Management
New York
$739K +$906K +5,000 New
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$711K +$499K +2,754 +134%
N
17
Nuveen
North Carolina
$694K -$192K -1,059 -18%
Two Sigma Investments
18
Two Sigma Investments
New York
$682K +$837K +4,616 New
Two Sigma Advisers
19
Two Sigma Advisers
New York
$550K +$674K +3,720 New
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$493K +$244K +1,347 +68%
GCP
21
GSA Capital Partners
United Kingdom
$452K -$546K -3,011 -50%
DC
22
Davenport & Co
Virginia
$440K – – –
First Trust Advisors
23
First Trust Advisors
Illinois
$397K +$40.2K +222 +9%
JP Morgan Chase
24
JP Morgan Chase
New York
$379K +$23.9K +132 +5%
TAM
25
Tocqueville Asset Management
New York
$344K -$49.8K -275 -11%
1
2 3

NBSE Hedge Fund Activity: Q1 2021 in Review

56 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2021, worth a combined $59.3M — up 21% from $49M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new NBSE positions and 8 closed out — a net gain of 3 holders — while 19 added to existing stakes and 15 trimmed.

The largest buyer was Polar Asset Management Partners, opening a new position worth an estimated $5.75M. The largest seller was Renaissance Technologies, cutting an estimated $2.05M.

  • 56 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2021, up from 53 in Q4 2020.
  • Funds reported $59.3M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2021, up 21% quarter-over-quarter.
  • 11 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2021 and 8 closed out, a net change of +3 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2021 was Polar Asset Management Partners, an estimated $5.75M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2021 was Renaissance Technologies, an estimated $2.05M sold.

Based on aggregated 13F filings for Q1 2021.